FITZSIMMONS PETER D

CEO Peter Fitzsimmons bought 12,750 shares of MNRO at $19.68 on 2026-02-05; second consecutive purchase in two days; stock +18.5% over 90 days.

FITZSIMMONS PETER D, President and CEO, purchased 12,750 shares (12.8K shares) at $19.68 on 2026-02-05, bringing his holdings to 112,033 shares (112.0K shares). This represents a 12.8% increase in his position from 99,283 shares (99.3K shares) and follows a purchase two days prior on 2026-02-03. The transaction occurred at a price 6.4% below the current market price of $21.04 and represents the second open-market buy in as many days, suggesting sustained acquisition activity. The company faces headwinds: annual revenue declined 6.4% year-over-year and reported negative full-year net income, though the latest quarter showed $293,387,000.00 in revenue and $11,139,000.00 in net income. With a market cap of $631,613,646.40, the CEO's repeated purchases near recent lows (current price -1.9% from the 52-week high of $21.44) warrant investor scrutiny regarding the company's operational recovery prospects.

CEO FITZSIMMONS buys 13,350 MNRO shares at $18.80 amid -6.4% revenue decline and full-year unprofitability

FITZSIMMONS PETER D, President and CEO of MONRO, INC., purchased 13,350 shares at $18.80 on 2026-02-03, increasing his holdings by 15.5% to 99,283 shares total. The purchase occurred with the stock trading at $20.14 (current), within its 52-week range of $12.22–$21.44 and 6.1% below the 52-week high. The company's fundamentals show significant headwinds: annual revenue declined 6.4% to $293,387,000.00, the company posted a net loss over its most recent full fiscal year (net income was negative), and latest quarterly net income stands at $11,139,000.00 on revenue of $293,387,000.00. The open-market purchase represents an affirmative capital commitment by the CEO at a time when the company is shrinking and unprofitable on a full-year basis. This buy-in by the top executive provides a direct counterweight to the negative growth trend, though the timing and sizing relative to company performance warrant investor scrutiny.